uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Show others and affiliations
2011 (English)In: Investigational new drugs, ISSN 0167-6997, E-ISSN 1573-0646, Vol. 29, no 5, 984-995 p.Article in journal (Refereed) Published
Abstract [en]

In cancer chemotherapy neutropenia is a common dose-limiting toxicity. An ability to predict the neutropenic effects of cytotoxic agents based on proposed trial designs and models conditioned on previous studies would be valuable. The aim of this study was to evaluate the ability of a semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model for myelosuppression to predict the neutropenia observed in Phase I clinical studies, based on parameter estimates obtained from prior trials. Pharmacokinetic and neutropenia data from 5 clinical trials for diflomotecan and from 4 clinical trials for indisulam were used. Data were analyzed and simulations were performed using the population approach with NONMEM VI. Parameter sets were estimated under the following scenarios: (a) data from each trial independently, (b) pooled data from all clinical trials and (c) pooled data from trials performed before the tested trial. Model performance in each of the scenarios was evaluated by means of predictive (visual and numerical) checks. The semi-mechanistic PK/PD model for neutropenia showed adequate predictive ability for both anti-cancer agents. For diflomotecan, similar predictions were obtained for the three scenarios. For indisulam predictions were better when based on data from the specific study, however when the model parameters were conditioned on data from trials performed prior to a specific study, similar predictions of the drug related-neutropenia profiles and descriptors were obtained as when all data were used. This work provides further indication that modeling and simulation tools can be applied in the early stages of drug development to optimize future trials.

Place, publisher, year, edition, pages
2011. Vol. 29, no 5, 984-995 p.
Keyword [en]
Neutropenia, Semi-mechanistic model, Diflomotecan, Indisulam, NONMEM
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-158566DOI: 10.1007/s10637-010-9437-zISI: 000294223500029OAI: oai:DiVA.org:uu-158566DiVA: diva2:440595
Available from: 2011-09-13 Created: 2011-09-12 Last updated: 2011-09-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Investigational new drugs
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 172 hits
ReferencesLink to record
Permanent link

Direct link